Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough

Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.